ArticleFrontiers in immunology2026
Efficacy of voriconazole combined with caspofungin in treating Chronic Obstructive Pulmonary Disease patients with invasive pulmonary aspergillosis: impacts on clinical outcomes, inflammatory cytokines, and immune markers.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy and safety of voriconazole plus caspofungin versus voriconazole alone in COPD patients with invasive pulmonary aspergillosis (IPA) and to determine whether the combination accelerates symptom resolution, reduces fungal and inflammatory load, and improves lung function and quality of life. Methodology: We retrospectively analyzed 152 COPD-IPA patients treated between April 2022 and April 2024, divided into an observation group (voriconazole + caspofungin, n=76) and control group (voriconazole alone, n=76). Outcomes included clinical efficacy, symptom resolution, inflammatory markers, and safety. Results: The observation group demonstrated superior outcomes including higher total efficacy (89.47% vs. 65.79%, P<0.05), faster symptom relief (cough: 5.36 vs. 7.89 days; fever: 7.06 vs. 9.44 days; P<0.05), and shorter hospitalization (12.28 vs. 15.62 days, P<0.05). Post-treatment analysis revealed lower β-D-glucan levels (15.64 vs. 20.16 pg/mL), reduced inflammatory markers (CRP, IL-12, IL-15, IL-17, TNF-α; P<0.05), and improved lung function (FEV1/FVC: 57.56% vs. 54.02%, P<0.05). Quality of life scores significantly improved (P<0.05) with comparable adverse events (7.89% vs. 13.16%, P>0.05). Conclusion: Voriconazole combined with caspofungin in oral sequential treatment of COPD combined with IPA can accelerate the relief of clinical symptoms and signs of patients, inhibit pathogenic bacteria and inflammatory response, improve lung function and quality of life of patients, improve efficacy, safety and reliability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.